Search NLS News

Alligator Bioscience and Amphera have announce the successful dosing of the last patient in the REACTIVE-2 Phase 1 trial evaluating mitazalimab in combination with MesoPher in patients with metastatic pancreatic cancer. The open-label, single-center Phase 1 dose finding study is assessing the safety and efficacy of Alligator’s lead asset mitazalimab, in combination with Amphera’s cancer […]

Elekta Esprit, a high precision stereotactic radiosurgery device, used to treat targets in the brain, such as tumors, vascular malformations, or functional disorders, has been awarded the Red Dot Award for product design in the medical devices and technology design category. According to the Red Dot organization, its award represents global recognition of belonging to […]

BioInvent International has announced that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma (NHL). The study is recruiting patients with NHL who have […]

The Royal Institute of Art and SciLifeLab have connected the creative minds of artists and scientists and the outcome of this fusion is explored in an exhibition at SciLifeLab campus. In February 2023, scientists and art students were given the possibility to present their respective fields to each other through the initiative Coalescence; Scientific research […]

Clinical trials play a crucial role in advancing medical research and bringing new and innovative treatments to the market. The Nordic region is known for its strong life science research and development, as well as unique health data. Performing clinical trials in the region is not without its challenges, but these can be overcome through […]

The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization for Ximluci (ranibizumab), a biosimilar referencing Lucentis. Under the co-development agreement in operation since […]

Ultimovacs has adjusted guidance from the first half of 2023 to the second half of 2023 for communication of topline progression free survival (PFS) data from the INITIUM Phase II trial in malignant melanoma patients. “We are encouraged that disease progression in the INITIUM trial is slower than anticipated when compared with historical data. This […]

SynAct Pharma has completed patient recruitment to the company’s clinical trial EXPAND which is evaluating its lead candidate compound AP1189 in early Rheumatoid Arthritis (RA) patients with severe disease activity. With all patients included into the study, dosing will be concluded in July and the last patient’s safety follow-up visit to be conducted in August. […]

On March 16, Peter Asplund’s report on clinical trials in Sweden was presented, containing proposals that should contribute to a long-term competitive and sustainable environment for clinical trials – with a special focus on company-initiated clinical trials in Sweden. SwedenBIO’s task force on clinical trials comments on the investigation through Maja Neiman, Science Relations Manager: […]

The companies have signed a collaboration and distribution agreement that gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe. “Partnering with Thermo Fisher, the leading innovator in the HLA industry, is a great opportunity for Devyser and a significant milestone for our company. […]